Introduction
Familial hypercholesterolaemia (FH) is characterized by the clinical triad of primary hyper-low-density lipoprotein (LDL) cholesterolaemia, tendon xanthomas and pre-mature coronary artery disease (CAD) 1 that is caused by genetic mutation(s) in several genes associated with LDL metabolism, such as LDL receptor (LDLR), apolipoprotein B (APOB) and proprotein convertase subtilisin/kexin type 9 (PCSK9). 2 Most diagnostic criteria for FH, such as those of the Dutch Lipid Clinic Network, the Simon Broome Register Group and the Japan Atherosclerosis Society, include tendon xanthomas, family history and mutation(s) in FH genes in addition to an elevated LDL cholesterol level. [3] [4] [5] Guidelines acknowledge that patients with FH are at high risk for CAD. 6 showed that LDL cholesterol > _190 mg/dL (FH phenotype) alone increased CAD risk substantially. 9 However, the impact of clinical signs, i.e. xanthomas and/or family history and genetic FH diagnosis on CAD risk beyond that of LDL cholesterol has not been well-investigated. In this study, we assessed whether clinical signs and genetic diagnosis of FH affected CAD risk among individuals with significantly elevated LDL cholesterol levels (> _180 mg/dL, > _140 mg/dL in subjects <15 years of age).
Methods

Study population
This retrospective study analysed data from 942 subjects with serum LDL cholesterol levels > _180 mg/dL (> _140 mg/dL for subjects < 15 years of age) and no known secondary cause for increased LDL levels among 20 453 subjects whose LDL cholesterol levels were previosuly measured at the Department of Internal Medicine of Kanazawa University Hospital between April 2000 and March 2012. A total of 299 subjects were excluded due to incomplete data. Seven subjects who were subsequently found to be homozygous for FH were also excluded. Thus, 636 subjects (mean age, 45 years; 300 males [47%]; CAD diagnosis, 185 [29%]) were included in final analysis ( Figure 1 ).
Clinical signs of familial hypercholesterolaemia
In addition to a significant elevation in LDL cholesterol, the following clinical FH signs were examined: (i) tendon xanthoma (on the backs of hands, elbows, knees, etc. or Achilles tendon hypertrophy by X-ray assessments of Achilles tendon thickness > _9 mm) or xanthoma tuberosum and (ii) family history of FH or pre-mature CAD among the subject's seconddegree relatives according to the criteria by the Japan Atherosclerosis Society. 5 
Genetic analysis
The coding regions of FH-associated genes (LDLR and PCSK9) were sequenced, and subject genotypes were determined as described elsewhere. 10 The most common APOB mutation (p.Arg3527Gln) was screened using methods reported previously. 11 Multiplex ligationdependent probe amplification method for large rearrangements was performed using a P062B LDLR MLPA kit (MRC Holland, Amsterdam, Netherlands). A variant was considered as a causative mutation if it fulfilled any of the following criteria: (i) loss-of-function mutation including non-sense mutation, insertion/deletion, frameshift or splice-site mutation; (ii) matching phenotype-genotype segregation pattern in >2 individuals; (iii) missense variants detected in LDLR predicted to be deleterious (scaled C-score >10) using an in silico annotation tool that integrates several different tools 12 ; or (iv) variants in LDLR or PCSK9 annotated as pathogenic in Clinvar. 
Classification of subjects with significantly elevated low-density lipoprotein cholesterol levels
Subjects with elevated LDL cholesterol levels were categorized into four groups based on the clinical FH signs and FH mutations ( Figure 1 ).
Ethical considerations
This study was approved by the ethics committee of the Kanazawa University. All procedures were conducted in accordance with the ethical standards of the responsible institutional and national committees on human experimentation and the 1975 Declaration of Helsinki, as revised in 2008. Informed consent for genetic analyses was obtained from all subjects prior to inclusion in the study.
Biochemical analysis
Blood samples for assays were drawn after overnight fasting. Serum levels of total cholesterol, triglycerides, and high-density lipoprotein (HDL) cholesterol were enzymatically determined (Qualigent, Sekisui Medical, Tokyo, Japan) using automated instrumentation as described elsewhere. 13 LDL cholesterol levels were calculated by Friedewald formula for samples with triglyceride levels <400 mg/dL; otherwise, it was determined enzymatically. For the majority of subjects (614/636, 97%), data prior to the introduction of lipid-lowering therapies were included in the analyses, whereas in the remaining subjects with a median 10-month period of lipid-lowering therapies, baseline values were determined after temporary discontinuation of therapy for about 4 weeks.
Clinical evaluation
Hypertension was defined as a systolic blood pressure of > _140 mmHg, a diastolic blood pressure of > _90 mmHg or prior use of antihypertensive medication. Diabetis diagnosis was based on criteria previously described by the Japan Diabetes Society 14 or the use of antidiabetic medication.
CAD was defined by the presence of angina pectoris, myocardial infarction or severe stenotic region(s) in coronary arteries (> _75%) identified by either angiography or computed tomography or by electrocardiogram in infantile cases (see Supplementary material online, Table S1 ).
Statistical analysis
Categorical variables were expressed as percentages. Fisher's exact test or the chi-squared test was used to assess between-group differences, as appropriate. Continuous variables with a normal distribution were presented as means ± standard deviation (SD). For non-normally distributed variables, medians with interquartile ranges were reported. Mean values of continuous variables were compared with Student's t-test for independent data, whereas median values were compared with the non-parametric Wilcoxon Mann-Whitney rank-sum test. Odds ratios (ORs) for CAD were calculated using logistic regression with adjustment for age, sex, hypertension, diabetes, smoking, and LDL cholesterol (model 1). Model 1 was used to calculate ORs for CAD based on the clinical FH signs and/or FH mutation status. Receiver-operating characteristic analysis was performed and C-statistic was calculated to estimate the predictive performance of considered parameters. C-statistic estimates were compared using the method by DeLong et al., and net reclassification improvement (NRI) and integrated discrimination improvement (IDI) were calculated. The Cochran-Armitage trend test was used to compare CAD prevalence and the presence of clinical signs. All statistical analyses were conducted using R V R statistical software. All two-tailed P values <0.05 were considered indicative of statistically significant between-group differences.
Results
Characteristics of study subjects
Clinical characteristics of study subjects are summarized in Table 1 . A total of 482 (76%) subjects exhibited either xanthoma or family history. In addition, FH mutations were detected in 502 (79%) subjects out of a total of 636 subjects with significantly elevated LDL cholesterol levels. As a result, the subjects included in this study were categorized into four groups based on the presence of clinical FH signs and FH mutations. Baseline characteristics of these groups are summarized in Table 2 . There were no significant differences in age, gender or LDL cholesterol levels between individuals included in the final analysis and those excluded due to any missing data (see Supplementary material online, 
Genetic background of subjects
Similar to our previous observation, 15 a non-sense mutation in LDLR (c.2431A > T, p.Lys811X) was observed frequently in our cohort (n = 197, 39.2%, see Supplementary material online, Table S3 ). In addition, none of the subjects in this cohort harboured the FH-causative mutation in APOB (p.Arg3527Gln), whereas a gain-of-function mutation in PCSK9 (c.94G > A, p.Glu32Lys) was observed relatively frequently (n = 37, 7.4%), in agreement with our previous findings.
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Prevalence of coronary artery disease according to age
As expected, CAD prevalence was higher in older age groups, both in males (see Supplementary material online, Figure S1A , 16.4%, 25.6 %, 62.0%, and 64.1% for each age quartile, respectively, P-trend = 0. 0255) and in females (see Supplementary material online, Figure S1B , 0%, 8.4%, 20.0%, and 39.6% for each age quartile, respectively, P-trend = 0.011).
Prevalence of coronary artery disease according to the clinical and genetic familial hypercholesterolaemia status Table S4 . These trends did not change by sub-group analysis disaggregated by sex (see Supplementary material online, Figure S2 ). Rather, we found that the impact of FH mutation/clinical signs of FH was stronger in females than in males (all P values for interaction <0.1).
Risk discrimination by positive familial hypercholesterolaemia mutation or positive clinical familial hypercholesterolaemia signs beyond traditional risk factors
The C-statistic, which was 0.897 for the traditional risk factors model, increased to 0.903 after addition of the positive FH mutation status (see Supplementary material online, Figure S3 , P = 0.044) and to 0.910 after addition of the positive clinical signs of FH (see Supplementary material online, Figure S3 , P = 0.00488). To assess the discriminatory potential of these parameters, continuous NRI and IDI were also assessed. We found that reclassification was improved by adding the positive FH mutation status (continuous NRI, 0.380; 95% CI, 0.229-0. 531; P < 0.001 and IDI, 0.017; 95% CI, 0.006-0.029; P = 0.004) or positive clinical FH signs (continuous NRI, 0.517; 95% CI, 0.382-0.652; P < 0.001 and IDI, 0.035; 95% CI, 0.019-0.051; P < 0.001) to the traditional risk factors model (see Supplementary material online, Tables S5 and S6).
Impact of mutation severity on lowdensity lipoprotein cholesterol level, clinical signs of familial hypercholesterolaemia and coronary artery disease
We found that severe mutations defined either as non-sense, frameshift or splice-site mutations had a stronger effect on LDL cholesterol levels (see Supplementary material online, Table S7 , 274 ± 64 mg/dL vs. 263 ± 14 mg/dL, P = 0.041) and the presence of clinical signs of FH (92% vs. 79%, P = 0.00011) than missense mutations, whereas the odds of developing CAD did not show a significant difference (see Supplementary material online, Figure S4 , OR, 4.4; 95% CI, 2.3-8.6, vs. OR, 4.0; 95% CI, 1.9-8.6). ) were independently associated with CAD, whereas diabetes was not a risk factor (OR, 1.43; 95% CI, 0.67-3.03; P = 0.255). (Table 3) .
Prevalence of factors associated with familial hypercholesterolaemia according to age
Xanthomas tended to be more frequent in older subjects (see Supplementary material online, Figure S5A , 24.8%, 49.1%, 55.2% and 49.4% for each age quartile, respectively, P-trend = 0.0478), whereas a positive family history of FH (see Supplementary material online, Figure S5B , 82.8%, 75.2%, 63.0%, and 51.9% for each age quartile, respectively, P-trend = 0.0219) and FH mutations (see Supplementary material online, Figure S5C , 89.8%, 82.4%, 75.3%, and 68.1% for each age quartile, respectively, P-trend = 0.0114) were more frequent in younger subjects.
Discussion
In this retrospective study of a cohort stratified according to the clinical signs and mutation status for FH, we found that the clinical signs of FH and a positive FH mutation status additively increased the risk for CAD in subjects with significantly elevated LDL cholesterol levels.
In a recent study, a significantly elevated LDL cholesterol level (FH phenotype) was associated with up to a five-fold increase in CAD odds compared with that associated with normal LDL cholesterol levels. 9 The authors simply defined a plasma LDL cholesterol level > _190 mg/dL as FH phenotype; however, another study showed that only a small fraction of individuals ($2%) amongst subjects with LDL cholesterol levels > _190 mg/dL harboured FH mutations without any assessment of other clinical signs of FH and that the positive FH mutation status increased the likelihood of CAD independent of the LDL cholesterol level. 8 In contrast, previous studies reported FH mutation rates among subjects with clinical signs of FH as 60-80%. 16, 17 These earlier findings prompted us to investigate the impact of clinical signs of FH and the genetic FH status on CAD prevalence. Previous reports showed that the presence of clinical signs of FH were significantly associated with CAD risk in prospective studies of FH patients with known mutation status. 18, 19 Our results strongly support these findings, highlighting the clinical usefulness of determination of both the FH mutation status and the clinical signs of FH in these patients. Several conclusions can be drawn from the current observations. First, assessment of both the clinical signs of FH and the genetic background of these subjects is critical. The current American College of Cardiology (ACC)/American Heart Association (AHA) Task Force guidelines (2013) for the prevention of atherosclerotic cardiovascular disease considers an LDL cholesterol level > _190 mg/dL as the criterion for identification of high-risk patients as well as those individuals who are likely to benefit from statin therapy. 20 However, identification of patients with FH by either clinical or genetic evaluation among those at high-risk individuals might accrue greater benefit. Secondly, clinical signs of FH and genetic status of FH were independently as well as additively associated with an increased risk for CAD in the current study, which might reflect the association of clinical FH signs with FH mutation status as well as other life-style factors or other unknown polygenetic causes. Additionally, we demonstrated that the presence of clinical signs of FH including xanthomas increased the risk of CAD beyond that contributed by a high LDL cholesterol level. Taking into consideration that other genetic conditions such as sitosterolaemia which do not result in elevated LDL cholesterol levels can lead to xanthomatosis and pre-mature CAD, there might be a yet unknown factor beyond LDL cholesterol that could explain the relationship between xanthomas and CAD.
Third, family history as well as genetic status appeared to be more important than physical findings in younger individuals. It is conceivable that such physical findings of FH might not be evident in younger individuals with true FH who are harbouring FH mutations. Accordingly, evaluation of family history in addition to their genetic status appears to be particularly important in younger subjects with severe hypercholesterolaemia. It is true that the efficacy of genetic testing would be more beneficial in younger individuals. Additionally, a recent study implicated that the presence of FH mutation(s) was insufficient to explain significant elevations in LDL cholesterol or premature CAD. 21 However, determination of genetic FH status not only in younger individuals with suspicious FH but also in older subjects should provide useful information not only for their offspring through cascade screening but also for their CAD risk stratification. 22 Accordingly, we recommend molecular testing in all individuals considered to be at risk for FH regardless of age. Fourth, known risk factors for CAD in the general population such as, age, sex, hypertension, smoking and elevated LDL cholesterol were associated with CAD in subjects with such an extreme phenotype in the current study.
Study limitations
The retrospective cross-sectional observational study design is a key limitation of the current study. However, our findings were based on one of the largest cohorts of Japanese patients with FH and CAD, which significantly contributed to our understanding of this subject across ethnicities. Moreover, our findings were consistent with previous studies. Secondly, subjects for whom relevant clinical and genetic data were not available were excluded from the final analysis, which might have introduced selection bias. Additionally, there might be a selection bias among the initial cohort of 942 subjects for whom genetic testing was strongly recommended due to physical findings of FH or a positive family history. However, we believe that our intensive assessment of such clinical signs as well as the impetus to collect detailed family history renders our phenotyping dataset comparable to other FH datasets across the world. Thirdly, while the presence of CAD was not assessed using angiogram or computed tomography in a small portion of subjects younger than 15 years of age (n = 29), all were evaluated by stress electrocardiography. None of the subjects exhibited positive signs, possibly leading to a bias, although the proportion of these patients within the study cohort was small. Fourthly, LDL cholesterol levels in the current study were higher than those reported in other studies, as patients with hyper-LDL cholesterolaemia were also included in the study. Finally, a portion of subjects (n = 24, 3%) had already received treatment, albeit for a relatively short time period, which might have affected the presence of xanthomas. However, we believe that the impact of these factors on the overall findings of the current study was minimal.
Conclusion
The findings of this retrospective study revealed an additive effect of positive clinical FH signs and positive FH mutation status on CAD risk among subjects with severe hypercholesterolaemia. Identification of patients with true FH by genetic testing and evaluation for positive clinical signs of FH might be useful for risk stratification among subjects with severe hypercholesterolaemia.
Supplementary material
Supplementary material is available at European Heart Journal online.
